Methods and agents for improving targeting of CD138 expressing tumor cells

US9446146B2 · kind B2 · utility

Assignees

• Biotest AG · DE
• IMMUNOGEN, INC. · US
• DANA-FARBER CANCER INSTITUTE, INC. · US

Inventors

• Benjamin Daelken · Frankfurt am Main, DE
• Christoph Uherek · Seligenstadt, DE
• Kenneth C. Anderson · Wellesley, US
• Teru Hideshima · Brookline, US
• Christoph Bruecher · Eschborn, DE
• Frank Osterroth · Dietzenbach, DE
• Silke Aigner · Bischofswerda, DE
• Matthias Germer · Langen, DE

Key dates

• Filing date: Dec 23, 2008
• Grant date: Sep 20, 2016
• Expiry date: Apr 23, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are immunoconjugates having specificity for CD138 that diminish adhesion of CD138 expressing tumor cells to stroma cells and methods of using the same. This diminished adhesion renders the tumor cells not only susceptible to the immunoconjugate, but also to other agents, in particular cytotoxic agents.